Previous 10 | Next 10 |
home / stock / alpmf / alpmf news
2024-02-05 08:06:35 ET More on Astellas Pharma Astellas Pharma Inc. 2023 Q3 - Results - Earnings Call Presentation FDA denies approval of Astellas gastric cancer drug Astellas and Elpiscience collaborate for novel bi-specific macrophage engagers Historical ea...
2024-01-26 12:58:45 ET More on Merck Merck & Co., Inc. (MRK) JPMorgan 42nd Annual Healthcare Conference (Slides) Merck & Co., Inc. (MRK) Presents at JPMorgan 42nd Annual Healthcare Conference (Transcript) Merck's Soaring Stock: Examining The Euphoria Amidst P...
2024-01-26 07:39:18 ET More on Apellis Pharmaceuticals Apellis Pharmaceuticals: Focus Shifts Toward Market Share After Apparent Safety Resolution Apellis Pharmaceuticals, Inc. (APLS) Q3 2023 Earnings Call Transcript Apellis Pharmaceuticals, Inc. 2023 Q3 - Results - E...
2024-01-14 12:00:24 ET More on CRISPR, GSK, etc. Pfizer Is Part Of The 2024 Healthcare Sector Rally Cohort Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry CRISPR Therapeutics AG (CRSP) 42nd Annual J.P. Morgan Healthcare Conference (Transcript) ...
2024-01-09 05:49:53 ET Japanese drugmaker Astellas Pharma ( OTCPK:ALPMY ) said on Monday that the U.S. Food and Drug Administration (FDA) has declined to approve the biologics license application of its experimental gastric cancer drug due to issues related to a third-party manufact...
2024-01-05 14:30:17 ET More on the markets SPY And QQQ: Fundamentals Remain Strong, Buying The Dip Verily Volatility: SPY Puts Are Cheap And The Market Is Selling Off The Market Looks Poised To Make New Highs In 2024 ETFs attract $597B in 2023 marking the fou...
2023-12-31 01:55:00 ET Summary Elpiscience Biopharma forms a $1.7 billion collaboration with Astellas Pharma to develop a bispecific macrophage engager. AstraZeneca acquires Gracell Biotech in a deal worth up to $1.2 billion, including a clinical stage CAR-T therapy. Jinan Qil...
2023-12-28 04:45:39 ET More on Astellas Pharma FDA approves Keytruda/Padcev combo therapy for bladder cancer Biden eyes seizing patents of taxpayer-funded drugs in bid to slash prices Seeking Alpha’s Quant Rating on Astellas Pharma ADR For further deta...
2023-12-27 12:29:36 ET More on AbbVie, Johnson & Johnson, etc. Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase Eli Lilly: Consider Cutting Before The Southbound Train Leaves (Rating Downgrade) AbbVie Vs. GSK: Dual Dominance In Pharma ...
2023-12-15 18:20:05 ET More on Merck, Pfizer, etc. Pfizer: Dividend Boost At The Right Time Pfizer 2024 Guidance - Relentless COVID Pain Isn't Over Johnson & Johnson Vs. Pfizer: Better Pharma Stock? Merck gets FDA approval for kidney cancer drug Welireg ...
News, Short Squeeze, Breakout and More Instantly...
Bayer AG (OTC:BAYRY) (OTC:BAYZF) will present detailed results from the Phase 3 studies OASIS 1 and 2, showing that the investi...
Merck & Co Inc (NYSE: MRK) announced that the Phase 3 AMBASSADOR (A031501) trial (KEYNOTE-123) evaluating Keytruda met one of its dual pri...
Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) (OTC: ALPMY) released topline results from the KEYNOTE-A39 Phase...